Allspring Global Investments’s Nektar Therapeutics NKTR Stock Holding History

Allspring Global Investments’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	2,991 +93	+3%	+$6.8K	﹤0.01%	1656
2026 Q1	$209K	Buy	+2,898	New	+$165K	﹤0.01%	1600
2023 Q1	–	Sell	-12,591	Closed	-$427K	–	2883
2022 Q4	$427K	Buy	12,591 +3,752	+42%	+$182K	﹤0.01%	1641
2022 Q3	$424K	Sell	8,839 -615	-7%	-$36.6K	﹤0.01%	1621
2022 Q2	$538K	Buy	9,454 +720	+8%	+$45.4K	﹤0.01%	1563
2022 Q1	$706K	Buy	8,734 +5,365	+159%	+$794K	﹤0.01%	2065
2021 Q4	$682K	Buy	+3,369	New	+$731K	﹤0.01%	2156

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allspring Global Investments's NKTR Position: Q2 2026 in Review

Allspring Global Investments increased its Nektar Therapeutics (NKTR) stake by 3.2% in Q2 2026, buying an estimated $6.8K and bringing the position to 2,991 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

Allspring Global Investments first reported a position in NKTR in Q4 2021 and has held it in 7 quarters since. The position peaked at $706K in Q1 2022. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Allspring Global Investments held 2,991 shares of Nektar Therapeutics worth $209K as of Q2 2026.
Allspring Global Investments bought 93 Nektar Therapeutics shares in Q2 2026, an estimated $6.8K.
Nektar Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1656 holding.
Allspring Global Investments first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 7 quarters since.
Allspring Global Investments's Nektar Therapeutics position peaked at $706K in Q1 2022.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.